Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Surveillance van patiënten met veronderstelde BD-IPMN overbodig?
jan 2024 | Maag-darm-leveroncologie